REGN

Regeneron Pharmaceuticals, Inc. News Headlines

$341.51
*  
3.77
1.09%
Get REGN Alerts
*Delayed - data as of Aug. 21, 2014  -  Find a broker to begin trading REGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
8/12/2014 5:20:00 PM - Zacks.com

The Case That Regeneron May Be Significantly Undervalued
8/8/2014 10:42:00 AM - Seeking Alpha

Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
8/6/2014 12:00:00 PM - Zacks.com

Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
8/5/2014 3:02:00 PM - Zacks.com

Nasdaq 100 Movers: EXPD, WFM
8/5/2014 12:21:38 PM - BNK Invest

Sector Update: Health Care Stocks Weighed in Pre-Market Trade
8/5/2014 8:25:25 AM - MT Newswires

Sector Update: Health Care
8/5/2014 8:20:15 AM - MT Newswires

Regeneron Pharma Q2 Profit Increases - Quick Facts
8/5/2014 6:42:00 AM - RTT News

Cramer's Mad Money - 4 Charts With Fangs (8/4/14)
8/5/2014 5:52:00 AM - Seeking Alpha

Pre-Market Earnings Report for August 5, 2014 : CVS, EMR, ACT, REGN, ADM, HCP, MMP, ZTS, MSI, FE, MGM, IEP
8/4/2014 4:00:01 PM - NASDAQ.com News

BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog
7/31/2014 5:00:00 PM - Zacks.com

Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
7/30/2014 7:00:00 PM - Zacks.com

BioMarin Sells Priority Review Voucher To Regeneron
7/30/2014 5:42:00 PM - Dow Jones Business News

S&P 500 Movers: GNW, EW
7/30/2014 11:28:22 AM - BNK Invest

Nasdaq 100 Movers: GRMN, REGN
7/30/2014 11:27:43 AM - BNK Invest

Regeneron Pharmaceuticals Inc. (REGN) Is Surging On Phase 3 Study Results
7/30/2014 9:32:00 AM - RTT News

Sanofi And Regeneron: 9 Phase 3 ODYSSEY Trials Of Alirocumab Met Primary Goal
7/30/2014 8:19:00 AM - RTT News

Sanofi, Regeneron's Alirocumab Shows Promise in Phase III Trials
7/30/2014 8:14:00 AM - Dow Jones Business News

ADMP Awaits Decision, REGN Can Catch Your Eye, SQNM Does A Deal, ZLTQ Goes Cool
7/30/2014 6:25:00 AM - RTT News

FDA Approves Bayer's Eylea for Diabetic Macular Edema Treatment
7/30/2014 3:50:00 AM - Dow Jones Business News

Cramer's Mad Money: The 4 Horsemen Trample Big Pharma (7/23/14)
7/24/2014 6:01:00 AM - Seeking Alpha

Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
7/22/2014 5:20:00 PM - Zacks.com

Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?
7/21/2014 10:40:00 AM - Seeking Alpha

InsiderInsights.com Daily Round Up: 7/17/14
7/18/2014 10:28:00 AM - Seeking Alpha

Sector Update: Health Care Shares Mixed Pre-Market
7/18/2014 8:45:52 AM - MT Newswires